Collegeville, PA, United States of America

Patrick Wilkinson

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Patrick Wilkinson in Vaccine Development

Introduction

Patrick Wilkinson, an accomplished inventor based in Collegeville, PA, is recognized for his significant contributions to the field of vaccine development. With one patent to his name, Wilkinson has demonstrated a commitment to addressing important medical challenges, particularly those associated with mutations in specific genes.

Latest Patents

Wilkinson's notable patent focuses on "Vaccines based on mutant CALR and JAK2 and their uses." This invention encompasses the development of vaccines, polypeptides, and polynucleotides derived from mutant CALR and JAK2 sequences. The patent also covers vectors, host cells, viruses, and various methods involved in making and utilizing these compositions. Moreover, it provides innovative methodologies for inducing immune responses and strategies for treating or preventing clinical conditions that are characterized by the expression of JAK2V617F or CALR exon 9 mutations, or a combination of both, emphasizing the method of administering these vaccines through a series of treatments.

Career Highlights

Currently, Patrick Wilkinson is associated with Janssen Biotech, Inc., where he contributes his expertise in biotechnology and vaccine research. His work is instrumental in advancing medical science and improving therapeutic outcomes for patients with specific genetic mutations.

Collaborations

In his professional journey, Wilkinson collaborates with talented colleagues such as Ricardo Attar and Jason DeHart. These partnerships foster a rich environment for innovation and enable the development of breakthrough medical solutions that aim to combat complex health issues.

Conclusion

Patrick Wilkinson stands out as a notable inventor in the realm of vaccine innovation, particularly through his work on mutant CALR and JAK2. His patent signifies not just an advancement in vaccine technology, but also a potential leap forward in the treatment and prevention of diseases linked to these mutations. As he continues his work at Janssen Biotech, Inc., the medical community eagerly anticipates further developments from this promising inventor.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…